Access cutting-edge b-cell lymphoma treatment through this clinical trial at a research site in Chapel Hill. Study-provided care at no cost to qualified participants.
Access b-cell lymphoma specialists in Chapel Hill at no cost
This study follows strict safety protocols and ethical guidelines
All study-related b-cell lymphoma treatment provided free
This phase II trial compares epcoritamab to standard practice (observation) for the treatment of patients with B-cell lymphomas who are not in complete remission after treatment with CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy. Epcoritamab is a bispecific antibody. It works by simultaneously attaching to a molecule called CD20 on cancerous B-cells and a molecule called CD3 on effector T-cells, which are a type of immune cell. When epcoritamab binds to CD20 and CD3, it brings t
Sponsor: Academic and Community Cancer Research United
Check if you qualify for this b-cell lymphoma clinical trial in Chapel Hill, NC
If you're searching for b-cell lymphoma treatment options in Chapel Hill, NC, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Chapel Hill research site is actively enrolling participants for this clinical trial. You'll receive care from experienced b-cell lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.